Imaging apoptosis with positron emission tomography: ‘Bench to bedside’ development of the caspase-3/7 specific radiotracer [18F]ICMT-11

Wahl, 2009, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307 Carden, 2009, From darkness to light with biomarkers in early clinical trials of cancer drugs, Clin Pharmacol Ther, 85, 131, 10.1038/clpt.2008.223 Kamb, 2007, Why is cancer drug discovery so difficult?, Nat Rev Drug Discovery, 6, 115, 10.1038/nrd2155 Aboagye, 2002, The use of imaging to accelerate drug development, Drug Discovery Today, 7, 706, 10.1016/S1359-6446(02)02342-5 Aboagye, 2006, Imaging in drug development, Clin Adv Hematol Oncol, 4, 902 Contractor, 2009, Monitoring predominantly cytostatic treatment response with 18F-FDG PET, J Nucl Med, 50, 97S, 10.2967/jnumed.108.057273 Gupta, 2002, PET for in vivo pharmacokinetic and pharmacodynamic measurements, Eur J Cancer, 38, 2094, 10.1016/S0959-8049(02)00413-6 Rosso, 2009, A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients, Cancer Res, 69, 120, 10.1158/0008-5472.CAN-08-2356 Saleem, 2000, Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action, Lancet, 355, 2125, 10.1016/S0140-6736(00)02380-1 Workman, 2006, Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies, J Natl Cancer Inst, 98, 580, 10.1093/jnci/djj162 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Juweid, 2006, Positron-emission tomography and assessment of cancer therapy, N Engl J Med, 354, 496, 10.1056/NEJMra050276 Weber, 2006, Monitoring chemotherapy and radiotherapy of solid tumors, Eur J Nucl Med Mol Imaging, 33, 27, 10.1007/s00259-006-0133-3 Mankoff, 2007, Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond, Clin Cancer Res, 13, 3460, 10.1158/1078-0432.CCR-07-0074 Sharma, 2011, Development of radiotracers for oncology – the interface with pharmacology, Br J Pharmacol, 163, 1565, 10.1111/j.1476-5381.2010.01160.x Aboagye, 2010, The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture, Br J Radiol, 83, 814, 10.1259/bjr/77317821 Reed, 2002, Apoptosis-based therapies, Nat Rev Drug Discovery, 1, 111, 10.1038/nrd726 Storey, 2008, Targeting apoptosis: selected anticancer strategies, Nat Rev Drug Discov, 7, 971, 10.1038/nrd2662 Chang, 2000, Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma, Cancer, 89, 2145, 10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S Dubray, 1998, In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin’s lymphomas, Radiother Oncol, 46, 185, 10.1016/S0167-8140(97)00148-5 Taylor, 2008, Apoptosis: controlled demolition at the cellular level, Nat Rev Mol Cell Biol, 9, 231, 10.1038/nrm2312 Reshef, 2010, Small-molecule biomarkers for clinical PET imaging of apoptosis, J Nucl Med, 51, 837, 10.2967/jnumed.109.063917 Yagle, 2005, Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis, J Nucl Med, 46, 658 Toretsky, 2004, Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death, Nucl Med Biol, 31, 747, 10.1016/j.nucmedbio.2004.02.007 Grierson, 2004, Production of [F-18]fluoroannexin for imaging apoptosis with PET, Bioconjugate Chem, 15, 373, 10.1021/bc0300394 Wang, 2011, Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I, J Nucl Med, 52, 592, 10.2967/jnumed.110.081588 Zhou, 2009, [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98, Org Biomol Chem, 7, 1337, 10.1039/b819024k Faust, 2007, The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent, Q J Nucl Med Mol Imaging, 51, 67 Podichetty, 2009, Fluorinated isatin derivatives. Part 1: synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors, Bioorg Med Chem, 17, 2680, 10.1016/j.bmc.2009.02.048 Podichetty, 2009, Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis, J Med Chem, 52, 3484, 10.1021/jm8015014 Nguyen, 2009, Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide, Proc Nat Acad Sci U.S.A., 106, 16375, 10.1073/pnas.0901310106 Smith, 2008, Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide, J Med Chem, 51, 8057, 10.1021/jm801107u Madar, 2007, Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation, Eur J Nucl Med Mol Imaging, 34, 2057, 10.1007/s00259-007-0500-8 Madar, 2009, Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium, J Nucl Med, 50, 774, 10.2967/jnumed.108.061283 Cohen, 2009, From the Gla domain to a novel small-molecule detector of apoptosis, Cell Res, 19, 625, 10.1038/cr.2009.17 Reshef, 2008, Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET, J Nucl Med, 49, 1520, 10.2967/jnumed.107.043919 Hoglund, 2011, 18F-ML-10, a PET tracer for apoptosis: first human study, J Nucl Med, 52, 720, 10.2967/jnumed.110.081786 Porter, 1999, Emerging roles of caspase-3 in apoptosis, Cell Death Differ, 6, 99, 10.1038/sj.cdd.4400476 Lee, 2000, Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality, J Biol Chem, 275, 16007, 10.1074/jbc.275.21.16007 Lee, 2001, Potent and selective nonpeptide inhibitors of caspases 3 and 7, J Med Chem, 44, 2015, 10.1021/jm0100537 Aulabaugh, 2007, Biochemical and biophysical characterization of inhibitor binding to caspase-3 reveals induced asymmetry, Biochemistry, 46, 9462, 10.1021/bi7000505 Smith, 2009, Translational imaging of apoptosis, Anticancer Agents Med Chem, 9, 958, 10.2174/187152009789377709 Glaser, 2011, Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation, Bioorg Med Chem Lett, 21, 6945, 10.1016/j.bmcl.2011.10.001 Belhocine, 2002, Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis, Clin Cancer Res, 8, 2766 Kemerink, 2003, Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application, J Nucl Med, 44, 947 Rottey, 2009, Influence of chemotherapy on the biodistribution of [99mTc]hydrazinonicotinamide annexin V in cancer patients, Q J Nucl Med Mol Imaging, 53, 127 Haas, 2004, In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients, Int J Radiat Oncol Biol Phys, 59, 782, 10.1016/j.ijrobp.2003.11.017 Kartachova, 2004, In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response, Radiother Oncol, 72, 333, 10.1016/j.radonc.2004.07.008 Kartachova, 2007, Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer, J Clin Oncol, 25, 2534, 10.1200/JCO.2006.10.1337 Kartachova, 2008, 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome, Nucl Med Commun, 29, 39, 10.1097/MNM.0b013e3282f1bc22 Hoebers, 2008, 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy, Eur J Nucl Med Mol Imaging, 35, 509, 10.1007/s00259-007-0624-x van de Wiele, 2003, Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography, J Clin Oncol, 21, 3483, 10.1200/JCO.2003.12.096 Shirvan, 2009, Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastasis to radiotherapy, J Nucl Med, 50, 118P International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication. New York: Pergamon Press;1979:30.